Tests an implanted device in adults with mild to moderate open-angle glaucoma
Tests the iStent infinite device in adults with mild to moderate glaucoma.
Plain-language title generated from the registry record
Registry title: Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Key facts
- Where
- Cincinnati, United StatesSee the site
Where in United States
- CincinnatiCincinnati, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Glaukos Corporation
- Trial code
- NCT06057051
- Record updated
- 28 September 2023
- Original description
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatmentRead full original descriptionShow less
A Prospective, Multicenter Study of the Glaukos® iStent Infinite Trabecular Micro-Bypass System Model iS3 in Subjects With Mild to Moderate Primary Open-angle Glaucoma
Prospective, multicenter, single-arm study of the iStent infinite in adult pseudophakic or phakic subjects with mild to moderate primary open angle glaucoma who have not failed conventional medical and surgical treatment
Inclusion: Diagnosis of primary open-angle glaucoma; Phakic or pseudophakic; Age 35 years or older.
Exclusion: glaucoma associated with vascular disorders; Retinal disorders not associated with glaucoma; Traumatic, uveitic, neovascular, angle-closure glaucoma or; Active corneal inflammation or edema.